Results 251 to 260 of about 2,169,697 (309)
Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers
ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt +5 more
wiley +1 more source
Predicting Loss of Ambulation in Limb Girdle Muscular Dystrophy R9
ABSTRACT Background Limb girdle muscular dystrophy type R9 (LGMDR9) results from biallelic variants in FKRP. There is limited data to predict loss of ambulation (LOA) among those with LGMDR9. Methods Participants in an ongoing dystroglycanopathy natural history study (NCT00313677) with FKRP variants who had achieved ambulation and were more than 3 ...
Chandra L. Miller +6 more
wiley +1 more source
Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Complex intensive care unit interventions
Critical Care Medicine, 2009The use of randomized controlled trials are useful for comparing a simple intervention such as a new drug or procedure. However, complex interventions such as a new system to evaluate early intervention in serious illness usually require complex research methodologies.
Ken, Hillman, Jack, Chen, Emily, May
openaire +2 more sources
Additional requirements for complex interventions
BMJ, 2012Similar to drug companies, developers of complex interventions are also liable to conflicts of interest that may bias results. We thus support the BMJ ’s decision to “publish only where there is a commitment to make the relevant anonymised patient level data available on reasonable request,”1 and we make suggestions that apply …
Thees F, Spreckelsen +2 more
openaire +2 more sources

